Drug profile · INN
cobicistat
TYBOST
cobicistat (TYBOST) is a cytochrome p450 3a inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — cobicistat
- US status
- approved
- Class
- Various (V03)
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
cobicistat (TYBOST) is a cytochrome p450 3a inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cytochrome P450 3A inhibitor
Primary target: Cytochrome P450 3A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is cobicistat?
cobicistat (TYBOST) is a cytochrome p450 3a inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for cobicistat?
TYBOST is a marketed brand name for cobicistat. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cobicistat?
cobicistat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.